製品番号: HY-B0220D

Erythromycin thiocyanate

24 Cited Publications

カスタマーレビュー

Based on 24 publication(s) in Google Scholar

Erythromycin thiocyanate is a macrolide antibiotic produced by actinomycete Streptomyces erythreus with a broad spectrum of antimicrobial activity. Erythromycin thiocyanate binds to bacterial 50S ribosomal subunits and inhibits RNA-dependent protein synthesis by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid^[1][2]. Erythromycin thiocyanate also exhibits antitumor and neuroprotective effect in different fields of research^[3][4].

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 96.42%
CAS 番号: 7704-67-8
分子式: C₃₈H₆₈N₂O₁₃S
分子量:793.02

保管条件:

-20°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Erythromycin thiocyanate 構造式

CAS 番号: 7704-67-8

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
化学情報
Publications (24)
溶剤 & 溶解度
- 体外
純度とドキュメンテーション
参考文献
Help & FAQs
Bioz

生物活性

製品説明

IC₅₀ & Target

Macrolide

Antibiotic アイソフォーム固有の製品をすべて表示 :

DNA/RNA Synthesis アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
HEK293	IC₅₀	>500 μM Compound: erythromycin	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	[PMID: 23241029]
HeLa	IC₅₀	>400 μg/mL Compound: Erythromycin	Antiproliferative effect against HeLa cells after 48 hrs Antiproliferative effect against HeLa cells after 48 hrs	[PMID: 17088489]
HeLa	IC₅₀	170 μg/mL Compound: Erythromycin	Inhibition of metabolic activity in HeLa cells assessed as MTT reduction after 48 hrs Inhibition of metabolic activity in HeLa cells assessed as MTT reduction after 48 hrs	[PMID: 17088489]
HFF	CC₅₀	475 μM Compound: 1	Cytotoxicity against HFF after 48 hrs by MTS assay Cytotoxicity against HFF after 48 hrs by MTS assay	[PMID: 21428405]
LLC-PK1	IC₅₀	>35 μM Compound: Erythromycin	Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay	[PMID: 12699389]
LLC-PK1	IC₅₀	>50 μM Compound: Erythromycin	Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay	[PMID: 12699389]
LLC-PK1	IC₅₀	>50 μM Compound: Erythromycin	Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay	[PMID: 12699389]
MG-63	IC₅₀	300 μg/mL Compound: Erythromycin	Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs	[PMID: 17088489]
MG-63	IC₅₀	310 μg/mL Compound: Erythromycin	Inhibition of metabolic activity in MG63 cells assessed as MTT reduction after 48 hrs Inhibition of metabolic activity in MG63 cells assessed as MTT reduction after 48 hrs	[PMID: 17088489]
Osteoblast	IC₅₀	>400 μg/mL Compound: Erythromycin	Inhibition of metabolic activity in primary human osteoblasts assessed as MTT reduction after 48 hrs Inhibition of metabolic activity in primary human osteoblasts assessed as MTT reduction after 48 hrs	[PMID: 17088489]
Osteoblast	IC₅₀	180 μg/mL Compound: Erythromycin	Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs	[PMID: 17088489]

体外実験

Erythromycin thiocyanate inhibits growth of P. falciparum with IC₅₀ and IC₉₀ values of 58.2 μM and 104.0 μM, respectively^[1].
Erythromycin thiocyanate (10 μM, 100 μM; 24 h, 72 h) shows antioxidant and anti-inflammatory effects and suppresses the accumulation of 4-HNE (p<0.01) and 8-OHdG (p<0.01), reduces Iba-1 (p<0.01) and TNF-α (p<0.01) expression significantly^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[4]

Cell Line:

Embryos primary cortical neuron (from the cerebral cortices of 17-day-old Sprague-Dawley rat)
Concentration:

10, 100 μM
Incubation Time:

24, 72 hours
Result:

Improved the viability of cultured neuronal cells in vitro after 3 hours oxygen-glucose deprivation (OGD).

体内実験

Erythromycin thiocyanate (gastric intubation; 0.1-50 mg/kg; 30-120 days) decreases tumor growth and prolong the survival time of mice from dose of 5 mg/kg in mice^[3].
Erythromycin thiocyanate (gastric intubation; 5 mg/kg) protects mice alive even at 120 days after inoculation, but shortens mean survival time in tumor-bearing mice by 4-5 days with dose of 50 mg/kg^[3].
Erythromycin thiocyanate (i.h.; single injection; 50 mg/kg) has a protective effect on the rat model with cerebral ischemia reperfusion-injury^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female ddY mice (6-week-old) with EAC cells or CDF mice (6-week-old) with P388 cells^[3]
Dosage:

0.1 mg/kg; 0.5 mg/kg; 10 mg/kg; 30 mg/kg; 50 mg/kg
Administration:

Gastric intubation; 30-120 days
Result:

Decreased tumor growth and prolonged the mean survival time of mice from the dose of 5 mg/kg, however, the 50 mg/kg dosage shortened the MST in tumorbearing mice.

Animal Model:

Male Sprague-Dawley rats (8-week-old, 250-300 g)^[4]
Dosage:

50 mg/kg
Administration:

Subcutaneous single injection
Result:

Reduced infarct volume and edema volume, improved neurological deficit.

化学情報

CAS 番号 7704-67-8
性状 Solid
分子量 793.02
分子式 C₃₈H₆₈N₂O₁₃S
Color White to off-white
SMILES

C[C@@H]([C@@H]([C@H](C(O[C@@H]1CC)=O)C)O[C@@](O[C@@H](C)[C@@H]2O)([H])C[C@@]2(C)OC)[C@H]([C@](O)(C[C@H](C([C@@H]([C@@H](O)[C@@]1(O)C)C)=O)C)C)O[C@@](O[C@H](C)C[C@@H]3N(C)C)([H])[C@@H]3O.SC#N
Structure Classification
- Antibiotics
- Macrolide Antibiotics
Initial Source
- Microorganisms
Streptomyces erythreHs
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

-20°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (24)

All Microbiological AssayRT-PCR

Sort by:

Journal Impact Factor

Acta Pharm Sin B

Repurposing carrimycin as an antiviral agent against human coronaviruses, including the currently pandemic SARS-CoV-2. [Abstract]

2021 Sep;11(9):2850-2858. PMID: 33723501
Theranostics

Antibiotic Azithromycin inhibits brown/beige fat functionality and promotes obesity in human and rodents. [Abstract]

2022 Jan 1;12(3):1187-1203. PMID: 35154482

Erythromycin thiocyanate purchased from MedChemExpress. Usage Cited in: Theranostics. 2022 Jan 1;12(3):1187-1203. [Abstract]

mRNA levels of thermogenic and mitochondrial gene programs in immortal beige and brown adipocytes treated with controls,erythromycin, azithromycin roxithromycin and telithromyc at 5 uM for 24 h (n=3).
EBioMedicine

A novel inhibitor of monooxygenase reversed the activity of tetracyclines against tet(X3)/tet(X4)-positive bacteria. [Abstract]

2022 Apr;78:103943. PMID: 35306337

Erythromycin thiocyanate purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2022 Apr;78:103943. [Abstract]

FIC indices of the combination of plumbagin (32 μg/mL) and Erythromycin against tet(X3)/tet(X4)-positive strains. Synergy was defined as an FIC index of ≤ 0.5.
J Exp Med

Antibiotic use in early life impairs MAIT cell-mediated immunity in adulthood. [Abstract]

2026 Mar 2;223(3):e20241287. PMID: 41400657
Chemosphere

Mass-balance-model-based evaluation of sewage treatment plant contribution to residual pharmaceuticals in environmental waters. [Abstract]

2019 Jun:225:378-387. PMID: 30884299
Biofabrication

Highly reproducible and cost-effective one-pot organoid differentiation using a novel platform based on PF-127 triggered spheroid assembly. [Abstract]

2023 Aug 21;15(4). PMID: 37552975
Emerg Microbes Infect

AMXT-1501 targets membrane phospholipids against Gram-positive and -negative multidrug-resistant bacteria. [Abstract]

2024 Dec;13(1):2321981. PMID: 38422452
Emerg Contam

2026 Feb 23.
J Med Chem

Activators of the Anticipatory Unfolded Protein Response with Enhanced Selectivity for Estrogen Receptor Positive Breast Cancer. [Abstract]

2022 Mar 10;65(5):3894-3912. PMID: 35080871
J Chem Inf Model

Macrolides May Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Entry into Cells: A Quantitative Structure Activity Relationship Study and Experimental Validation. [Abstract]

2021 Apr 26;61(4):2016-2025. PMID: 33734704
mLife

LipR functions as an intracellular pH regulator in Bacillus thuringiensis under glucose conditions. [Abstract]

2023 Feb 11;2(1):58-72. PMID: 38818337
Aquat Toxicol

Antibacterials exert toxic effects on aquatic organisms by inhibiting respiration, inducing oxidative stress, mitochondrial dysfunction and autophagy. [Abstract]

2025 Feb 9:280:107284. PMID: 39951902
BMC Microbiol

The antimicrobial activity of cethromycin against Staphylococcus aureus and compared with erythromycin and telithromycin. [Abstract]

2023 Apr 20;23(1):109. PMID: 37081393
Environ Microbiol

Expression of ribosomal protection protein RppA is regulated by a ribosome-dependent ribo-regulator and two mistranslation products. [Abstract]

2021 Feb;23(2):696-712. PMID: 32592275
Microbiol Spectr

Killing of colistin-resistant Aeromonas hydrophila by a synthetic peptide. [Abstract]

2025 Aug 29:e0059025. PMID: 40879403
Microbiol Spectr

The Mechanism of Action of Ginkgolic Acid (15:1) against Gram-Positive Bacteria Involves Cross Talk with Iron Homeostasis. [Abstract]

2022 Feb 23;10(1):e0099121. PMID: 35019708
AMB Express

Repurposing pinaverium bromide against Staphylococcus and its biofilms with new mechanisms. [Abstract]

2024 Dec 24;14(1):141. PMID: 39718732

Erythromycin thiocyanate purchased from MedChemExpress. Usage Cited in: AMB Express. 2024 Dec 24;14(1):141. [Abstract]

Combinational antimicrobial effects between PVB and conventional antibiotics against MRSA ATCC 43,300. TET, Tetracycline. DOX, Doxycycline. E, Erythromycin. AZI, Azithromycin. P, Penicillin. CAZ, Ceftazidime. AMP, Ampicillin. CEZ, Cefazolin. CEF, Cefotaxime. OXA, Oxacillin. CRO, Ceftriaxone. AMK, Amikacin. GEN, Gentamycin, KANA, Kanamycin. TOB, Tobramycin. SPC, Spectinomycin.
Viruses

Erythromycin Estolate Inhibits Zika Virus Infection by Blocking Viral Entry as a Viral Inactivator. [Abstract]

2019 Nov 15;11(11):1064. PMID: 31731598
Water

2025 Jun 6.
Vet Microbiol

Discovery of the tigecycline resistance gene cluster tmexCD3-toprJ1 in Pasteurella multocida strains isolated from pigs in China. [Abstract]

2024 May:292:110046. PMID: 38471428
bioRxiv

2024 May 10.
Research Square Print

December 5th, 2022.
Charles University

2020 Jul.
Research Square Preprint

2020 Jun.

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (126.10 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.2610 mL

6.3050 mL

12.6100 mL

5 mM

0.2522 mL

1.2610 mL

2.5220 mL

10 mM

0.1261 mL

0.6305 mL

1.2610 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (282 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Gribble MJ, et al. Erythromycin. Med Clin North Am. 1982 Jan;66(1):79-89. [Content Brief]

[2]. Nakornchai S, et al. Activity of azithromycin or erythromycin in combination with antimalarial drugs against multidrug-resistant Plasmodium falciparum in vitro. Acta Trop. 2006 Dec;100(3):185-91. Epub 2006 Nov 28. [Content Brief]

[3]. Hamada K, et al. Antitumor effect of erythromycin in mice. Chemotherapy. 1995 Jan-Feb. 41(1):59-69. [Content Brief]

[4]. Katayama Y, et al. Neuroprotective effects of erythromycin on cerebral ischemia reperfusion-injury and cell viability after oxygen-glucose deprivation in cultured neuronal cells. Brain Res. 2014 Nov 7. 1588:159-67. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.2610 mL	6.3050 mL	12.6100 mL	31.5251 mL
	5 mM	0.2522 mL	1.2610 mL	2.5220 mL	6.3050 mL
	10 mM	0.1261 mL	0.6305 mL	1.2610 mL	3.1525 mL
	15 mM	0.0841 mL	0.4203 mL	0.8407 mL	2.1017 mL
	20 mM	0.0631 mL	0.3153 mL	0.6305 mL	1.5763 mL
	25 mM	0.0504 mL	0.2522 mL	0.5044 mL	1.2610 mL
	30 mM	0.0420 mL	0.2102 mL	0.4203 mL	1.0508 mL
	40 mM	0.0315 mL	0.1576 mL	0.3153 mL	0.7881 mL
	50 mM	0.0252 mL	0.1261 mL	0.2522 mL	0.6305 mL
	60 mM	0.0210 mL	0.1051 mL	0.2102 mL	0.5254 mL
	80 mM	0.0158 mL	0.0788 mL	0.1576 mL	0.3941 mL
	100 mM	0.0126 mL	0.0631 mL	0.1261 mL	0.3153 mL

Keywords

Erythromycin thiocyanate

24 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Erythromycin thiocyanate

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Macrocyclic Compound Library

Antibacterial Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Neuroprotective Compound Library

Microbial Metabolite Library

Food-Sourced Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

Anti-Cancer Natural Product Library

Protein-protein Interaction Inhibitor Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Pulmonary Fibrosis Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Heterocyclic Compound Library

Off-patent Drug Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Mass Spectrometry Natural Product Library

MedChemExpress（MCE）の使用を引用している文献 Erythromycin thiocyanate

Antibiotic アイソフォーム固有の製品をすべて表示

DNA/RNA Synthesis アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (24)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Erythromycin thiocyanate 関連分類

製品番号: HY-B0220D